Posted from: Sunday, December 11, 2016 - 04:04 PM - Present

Opdivo Gains New Indication

November 10, 2016 – The US FDA approved a new indication for Opdivo® (nivolumab), manufactured by Bristol-Myers Squibb.  Opdivo is a programmed death receptor-1 (PD-1) checkpoint inhibitor. The monoclonal antibody was approved to treat patients who have squamous cell carcinoma of the head and neck (SCCHN) that has spread or come back despite prior or concurrent treatment with a platinum-based chemotherapy drug. As an immunotherapy agent, it enhances the ability of the immune system to attack and destroy cancer cells. In the clinical trial, CheckMate-14, the average overall survival rate was about 7.5 months for Opdivo-treated patients compared to about 5.1 months for patients treated with other standard drugs. For SCCHN, Opdivo is given once every two weeks through a 60-minute IV infusion that contains 3mg of drug for each Kg the patient weighs. Originally FDA approved Opdivo in December 2014 as a breakthrough therapy for advanced melanoma; it also has several additional indications, both alone and in combination with other drugs, to treat various types of cancer.


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, October 13, 2019 - 05:27 PM.